» Articles » PMID: 25045139

Newly Established ELISA for N-ERC/mesothelin Improves Diagnostic Accuracy in Patients with Suspected Pleural Mesothelioma

Overview
Journal Cancer Med
Specialty Oncology
Date 2014 Jul 22
PMID 25045139
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Pleural mesothelioma is an aggressive tumor, commonly caused by exposure to asbestos. The prognosis of mesothelioma remains disappointing despite multimodal treatment. We reported previously that N-ERC/mesothelin could be a useful biomarker for the early diagnosis of pleural mesothelioma and developed an enzyme-linked immunosorbent assay (ELISA) system for its detection. However, the reproducibility of our previous 7-16 ELISA system has been revealed to be unsatisfactory. To measure N-ERC/mesothelin more precisely, we developed a new 7-20 ELISA system. The subjects of this study were patients who were referred to our department with suspected pleural mesothelioma. The current study demonstrated that the newly established 7-20 ELISA system improved the sensitivity and specificity for diagnosing pleural mesothelioma compared with the previous system. Moreover, the 7-20 ELISA system showed better reproducibility and displayed the tendency of both higher sensitivity and higher specificity in plasma than in serum. Particularly for the epithelioid type, the area under the curve (AUC) and the diagnostic accuracy of N-ERC/mesothelin were excellent; the AUC was 0.91, the sensitivity was 0.95, and the specificity was 0.76 in plasma. In conclusion, assessment of N-ERC/mesothelin with our newly established 7-20 ELISA system is clinically useful for the precise diagnosis of pleural mesothelioma.

Citing Articles

Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.

Koyanagi A, Kajino K, Nojiri S, Abe M, Kobayashi T, Sugitani Y Juntendo Iji Zasshi. 2024; 69(2):124-136.

PMID: 38854453 PMC: 11153076. DOI: 10.14789/jmj.JMJ22-0042-OA.


Surface plasmon resonance biosensor with laser heterodyne feedback for highly-sensitive and rapid detection of COVID-19 spike antigen.

Dai Z, Xu X, Wang Y, Li M, Zhou K, Zhang L Biosens Bioelectron. 2022; 206:114163.

PMID: 35272216 PMC: 8898347. DOI: 10.1016/j.bios.2022.114163.


Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells.

Fujihira H, Takakura D, Matsuda A, Abe M, Miyazaki M, Nakagawa T J Biochem. 2021; 170(3):317-326.

PMID: 33792699 PMC: 8510291. DOI: 10.1093/jb/mvab044.


In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.

Hino O, Abe M, Han B, Yan Y Cancer Sci. 2019; 110(5):1518-1524.

PMID: 30888083 PMC: 6500980. DOI: 10.1111/cas.14001.


Biomarkers in the prevention and follow-up of workers exposed to asbestos.

Foddis R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A J Thorac Dis. 2018; 10(Suppl 2):S360-S368.

PMID: 29507806 PMC: 5830548. DOI: 10.21037/jtd.2017.12.17.


References
1.
Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O . Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003; 23(1B):531-6. View

2.
Pass H, Levin S, Harbut M, Melamed J, Chiriboga L, Donington J . Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012; 367(15):1417-27. PMC: 3761217. DOI: 10.1056/NEJMoa1115050. View

3.
Robinson B, Creaney J, Lake R, Nowak A, Musk A, de Klerk N . Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer. 2005; 49 Suppl 1:S109-11. DOI: 10.1016/j.lungcan.2005.03.020. View

4.
Pass H, Lott D, Lonardo F, Harbut M, Liu Z, Tang N . Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353(15):1564-73. DOI: 10.1056/NEJMoa051185. View

5.
Krug L, Pass H, Rusch V, Kindler H, Sugarbaker D, Rosenzweig K . Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009; 27(18):3007-13. PMC: 3646305. DOI: 10.1200/JCO.2008.20.3943. View